Home > Insider Trading > Filing (0001104659-23-028617)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1811623	Paxmedica Inc.	PXMD	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1809613	Michael Derby	C/O Paxmedica, Inc. 303 South Broadway, Suite 125 Tarrytown NY 10591	Executive Chairman	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-03-02	10,497	$1.94	374,503	No	4	S	Direct
Common Stock	Disposition	2023-03-03	18,968	$1.90	355,535	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,336,745	Indirect	TardiMed Sciences, LLC

Footnotes

The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan. Shares were sold by the Reporting Person to generate proceeds used to satisfy the tax withholding obligation that arose upon the vesting of restricted stock units granted to the Reporting Person.
This sale price represents the weighted average sale price of the shares sold ranging from $2.09 to $1.87 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
This sale price represents the weighted average sale price of the shares sold ranging from $1.98 to $1.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The reporting person is the Managing Partner of TardiMed and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.